Comparison of VerifyNow-P2Y12 test and flow cytometry for monitoring individual platelet response to clopidogrel. What is the cut-off value for identifying patients who are low responders to clopidogrel therapy?

被引：44

作者：

Godino C. ^{[1
,2
]}

Mendolicchio L. ^{[1
]}

Figini F. ^{[1
]}

Latib A. ^{[1
]}

Sharp A.S.P. ^{[2
]}

Cosgrave J. ^{[2
]}

Calori G. ^{[3
]}

Cera M. ^{[1
]}

Chieffo A. ^{[1
]}

Castelli A. ^{[1
]}

Maseri A. ^{[1
]}

Ruggeri Z.M. ^{[4
]}

Colombo A. ^{[1
,2
]}

机构：

[1] Department of Cardio-Thoracic and Vascular Diseases, San Raffaele Scientific Institute, Milan

[2] GVM Emo Centro Cuore Columbus, Milan

[3] Epidemiology and Medical Statistics Unit, San Raffaele Scientific Institute, Milan

[4] The Scripps Research Institute, Department of Molecular and Experimental Medicine, La Jolla, CA

来源：

Thrombosis Journal | / 7卷 / 1期

关键词：

Clopidogrel; Platelet Function; Stent Thrombosis; Eptifibatide; Clopidogrel Therapy;

D O I：

10.1186/1477-9560-7-4

中图分类号：

学科分类号：

摘要：

Background: Dual anti-platelet therapy with aspirin and a thienopyridine (DAT) is used to prevent stent thrombosis after percutaneous coronary intervention (PCI). Low response to clopidogrel therapy (LR) occurs, but laboratory tests have a controversial role in the identification of this condition. Methods: We studied LR in patients with stable angina undergoing elective PCI, all on DAT for at least 7 days, by comparing: 1) Flow cytometry (FC) to measure platelet membrane expression of P-selectin (CD62P) and PAC-1 binding following double stimulation with ADP and collagen type I either in the presence of prostaglandin (PG) E1; 2) VerifyNow-P2Y12 test, in which results are reported as absolute P2Y12-Reaction-Units (PRU) or % of inhibition (% inhibition). Results: Thirty controls and 52 patients were analyzed. The median percentage of platelets exhibiting CD62P expression and PAC-1 binding by FC evaluation after stimulation in the presence of PG E1 was 25.4% (IQR: 21.4-33.1%) and 3.5% (1.7-9.4%), respectively. Only 6 patients receiving DAT (11.5%) had both values above the 1st quartile of controls, and were defined as LR. Evaluation of the same patients with the VerifyNow-P2Y12 test revealed that the area under the receiver-operating-characteristic (ROC) curve was 0.94 (95% CI: 0.84-0.98, p < 0.0001) for % inhibition and 0.85 (0.72-0.93, p < 0.005) for PRU. Cut-off values of ≤ 15% inhibition or 213 PRU gave the maximum accuracy for the detection of patients defined as having LR by FC. Conclusion: In conclusion our findings show that a cut-off value of ≤ 15% inhibition or 213 PRU in the VerifyNow-P2Y12 test may provide the best accuracy for the identification of patients with LR. © 2009 Godino et al; licensee BioMed Central Ltd.

引用

共 26 条

[1]

Pereillo J.-M., Maftouh M., Andrieu A., Uzabiaga M.-F., Fedeli O., Savi P., Pascal M., Herbert J.-M., Maffrand J.-P., Picard C., Structure and stereochemistry of the active metabolite of clopidogrel, Drug Metab Dispo, 30, pp. 1288-1295, (2002)

[2]

Mehta S.R., Yusuf S., Peters R.J.G., Bertrand M.E., Lewis B.S., Natarajan M.K., Malmberg K., Rupprecht H.J., Zhao F., Chrolavicius S., Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: The PCI-CURE study, The Lancet, 358, pp. 527-533, (2001)

[3]

Yusuf S., Zhao F., Mehta S.R., Chrolavicius S., Tognoni G., Fox K.K., Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without st-segment elevation, N Engl J Med, 345, pp. 494-502, (2001)

[4]

Airoldi F., Colombo A., Morici N., Latib A., Cosgrave J., Buellesfeld L., Bonizzoni E., Carlino M., Gerckens U., Godino C., Et al., Incidence and predictors of drug-eluting stent thrombosis during and after discontinuation of thienopyridine treatment, Circulation, 116, pp. 745-754, (2007)

[5]

Stone G.W., Ellis S.G., Colombo A., Dawkins K.D., Grube E., Cutlip D.E., Friedman M., Baim D.S., Koglin J., Offsetting impact of thrombosis and restenosis on the occurrence of death and myocardial infarction after paclitaxel-eluting and bare metal stent implantation, Circulation, 115, pp. 2842-2847, (2007)

[6]

Serebruany V.L., Oshrine B.R., Malinin A.I., Atar D., Michelson A.D., Ferguson J.J., Noncompliance in cardiovascular clinical trials, Am Heart, 150, pp. 882-886, (2005)

[7]

Nguyen T.A., Diodati J.G., Pharand C., Resistance to clopidogrel: A review of the evidence, J Am Coll Cardiol, 45, pp. 1157-1164, (2005)

[8]

Lev E.I., Patel R.T., Maresh K.J., Guthikonda S., Granada J., DeLao T., Bray P.F., Kleiman N.S., Aspirin and clopidogrel drug response in patients undergoing percutaneous coronary intervention the role of dual drug resistance, J Am Coll Cardiol, 47, pp. 27-33, (2006)

[9]

Angiolillo D.J., Fernandez-Ortiz A., Bernardo E., Ramirez C., Barrera-Ramirez C., Sabate M., Hernandez R., Moreno R., Escaned J., Alfonso F., Et al., Identification of low responders to a 300-mg clopidogrel loading dose in patients undergoing coronary stenting, Thrombosis Research, 115, pp. 101-108, (2005)

[10]

Gurbel P.A., Bliden K.P., Hiatt B.L., O'Connor C.M., Clopidogrel for coronary stenting: Response variability, drug resistance, and the effect of pretreatment platelet reactivity, Circulation, 107, pp. 2908-2913, (2003)

← 1 2 3 →